Actively Recruiting
Phase 2 Randomized Study of Imzokitug with Pumitamig and Chemotherapy Versus Pumitamig and Chemotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer
Led by Bristol-Myers Squibb · Updated on 2026-10-23
160
Participants Needed
74
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of Imzokitug combined with Pumitamig and Platinum-Doublet Chemotherapy PDCT compared to Pumitamig and PDCT alone as first-line treatment for adults with locally advanced or metastatic Non-Small Cell Lung Cancer NSCLC. This Phase 2, randomized, open-label study is sponsored by Bristol-Myers Squibb and focuses on patients with stage IV or recurrent unresectable NSCLC. Participants are randomly assigned to one of several treatment groups receiving combinations of Pumitamig, Imzokitug, and histology-based PDCT drugs such as Pemetrexed, Cisplatin, Carboplatin, or Paclitaxel. Each drug is given in specified doses on designated days. The study compares the combination therapies over the treatment period to assess their impact on the cancer. During the trial, participants undergo assessments including tumor measurements using the RECIST v1.1 criteria to determine objective response rate and progression-free survival, along with monitoring for adverse events up to 90 days after treatment ends. The study also tracks overall survival, duration of response, and time to recurrence for up to about four years. Participants will be regularly evaluated by investigators throughout the study duration, which extends to the study completion date in 2030.
CONDITIONS
Brief Title
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here